BioSpace News Archive

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) submission has been reviewed, and Puma can proceed with the clinical development of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer (SCLC).

FOXO Technologies™ Sets Second Quarter 2023 Business Update Call for Thursday, August 10, 2023 at 3:15 p.m. CT.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today announced its second quarter 2023 financial results, reported on the progress of its clinical development pipeline, and provided an update on the Company’s sharpened strategic focus.

Regen BioPharma, Inc., a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on August 10, 2023.

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced the publication of preclinical research with IGV-001 in Journal for ImmunoTherapy of Cancer, the official journal of the Society for Immunotherapy of Cancer (SITC).

Celmatix Inc. and Aché Laboratórios, a leading Brazilian pharmaceutical company, announced a collaboration and license option agreement to jointly investigate a novel peripherally preferred melatonin receptor agonist, discovered by Aché, for Women’s Health indications.

ThermoGenesis Holdings, Inc. announced that the Company will release its financial results for the second quarter ended June 30, 2023, and provide a corporate strategic update on Thursday, August 10, 2023, after the close of trading.

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, reported financial and operating results for the second quarter and first half of 2023.

23andMe Holding Co., a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter of fiscal year 2024, which ended June 30, 2023.

X4 Pharmaceuticals, Inc. announced that Christophe Arbet-Engels, MD, PhD, will be joining the company as its new Chief Medical Officer, bringing more than 25 years’ experience in strategic global drug development across a wide range of therapeutic areas including rare and orphan diseases.